INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 112 filers reported holding INTELLIA THERAPEUTICS INC in Q4 2017. The put-call ratio across all filers is 0.73 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $314,575,638 | -19.0% | 9,948,629 | +4.4% | 2.41% | -6.4% |
| Q2 2023 | $388,467,484 | +6.0% | 9,525,931 | -3.2% | 2.57% | +2.1% |
| Q1 2023 | $366,631,177 | +11.5% | 9,837,166 | +4.4% | 2.52% | -11.5% |
| Q4 2022 | $328,691,084 | -39.2% | 9,420,782 | -2.4% | 2.85% | -24.4% |
| Q3 2022 | $540,409,000 | +23.1% | 9,657,052 | +1.5% | 3.77% | +45.1% |
| Q2 2022 | $439,003,000 | -32.7% | 9,514,580 | +5.9% | 2.60% | -4.7% |
| Q1 2022 | $652,651,000 | -30.3% | 8,981,029 | +13.4% | 2.72% | -3.7% |
| Q4 2021 | $936,092,000 | +3.5% | 7,916,882 | +17.4% | 2.83% | +30.3% |
| Q3 2021 | $904,648,000 | -27.3% | 6,743,556 | -12.2% | 2.17% | -6.2% |
| Q2 2021 | $1,244,188,000 | +61.3% | 7,684,441 | -20.1% | 2.32% | +51.1% |
| Q1 2021 | $771,404,000 | +26.7% | 9,611,911 | -14.1% | 1.53% | -5.4% |
| Q4 2020 | $608,827,000 | +168.5% | 11,191,670 | -1.9% | 1.62% | +20.4% |
| Q3 2020 | $226,726,000 | -5.4% | 11,404,752 | +0.0% | 1.34% | -47.8% |
| Q2 2020 | $239,699,000 | +91.4% | 11,403,379 | +11.4% | 2.58% | -17.4% |
| Q1 2020 | $125,226,000 | -2.3% | 10,239,286 | +17.1% | 3.12% | -3.5% |
| Q4 2019 | $128,237,000 | +13.4% | 8,741,432 | +3.2% | 3.23% | +31.0% |
| Q3 2019 | $113,082,000 | -16.2% | 8,470,576 | +2.8% | 2.47% | -27.4% |
| Q2 2019 | $134,941,000 | -1.0% | 8,243,165 | +3.3% | 3.40% | -12.7% |
| Q1 2019 | $136,319,000 | +46.8% | 7,981,198 | +17.3% | 3.90% | +3.3% |
| Q4 2018 | $92,847,000 | -43.6% | 6,801,952 | +18.2% | 3.77% | -24.2% |
| Q3 2018 | $164,673,000 | +33.3% | 5,753,790 | +27.5% | 4.98% | +10.0% |
| Q2 2018 | $123,492,000 | +62.5% | 4,513,584 | +25.3% | 4.52% | +19.9% |
| Q1 2018 | $75,987,000 | +187.5% | 3,602,976 | +162.0% | 3.77% | +79.2% |
| Q4 2017 | $26,430,000 | +844.9% | 1,375,149 | +686.7% | 2.10% | +286.2% |
| Q2 2017 | $2,797,000 | +148.6% | 174,810 | +118.9% | 0.54% | +68.2% |
| Q1 2017 | $1,125,000 | +223.3% | 79,850 | +200.8% | 0.32% | +155.1% |
| Q4 2016 | $348,000 | – | 26,544 | – | 0.13% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 1,216,340 | $62,958,000 | 7.04% |
| Discovery Value Fund | 584,483 | $30,253,000 | 6.33% |
| MPM BioImpact LLC | 299,409 | $15,497,000 | 4.30% |
| ARK Investment Management | 9,514,580 | $439,003,000 | 2.60% |
| Elmwood Wealth Management, Inc. | 67,899 | $3,514,000 | 2.00% |
| Nikko Asset Management Americas, Inc. | 2,781,136 | $141,143,000 | 1.74% |
| Avidity Partners Management LP | 1,125,194 | $58,240,000 | 1.34% |
| Merlin Capital, Inc | 12,174 | $630,000 | 1.26% |
| Atlas Venture Associates IX, LLC | 10,000 | $518,000 | 1.18% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 111,440 | $5,768,000 | 1.16% |